Why Is SGMO Stock Up 40% Today?
$Sangamo Therapeutics(SGMO.US$ stock is up after the company announced a successful late-stage trial.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US$ , adding a layer of clout to the R&D behind the prospective treatment.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US$ , adding a layer of clout to the R&D behind the prospective treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Ebere : This stock is going down this early morning.